Related Experiment Video
Updated: Sep 15, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
SLMO2 inhibits apoptosis in ovarian cancer cells by modulating mitochondrial function via TRIAP1
Yaqi Wang1, Yuesong Wang1, Zixuan Li2
1Department of Gynecology, Yantaishan Hospital, Yantai, Shandong, PR China.
Objective:
This study aimed to investigate the role of SLMO2 in regulating mitochondrial function and its interaction with TRIAP1, which inhibited apoptosis in ovarian cancer cells. The findings provided valuable insights into potential therapeutic targets for ovarian cancer.
Methods:
Lentiviral infection models were developed using SKOV3 and OVCAR3 ovarian cancer cell lines. Techniques such as flow cytometry, western blotting, immunofluorescence, and transmission electron microscopy were employed to systematically assess the regulatory effects of SLMO2 and TRIAP1 on cell proliferation, apoptosis, mitochondrial function, and autophagy. Additionally, a subcutaneous mouse tumor xenograft model was utilized to further investigate the combined effects of SLMO2 and TRIAP1 on ovarian cancer cells, with the aim of elucidating the specific mechanisms underlying tumor growth and apoptosis.
Results:
SLMO2 enhanced mitochondrial function by increasing membrane potential and reducing reactive oxygen species (ROS) levels. Furthermore, through its interaction with TRIAP1, SLMO2 inhibited autophagy, which further suppressed apoptosis in ovarian cancer cells and regulated mitochondrial function. In vivo experiments showed decreased ROS levels and reduced expression of autophagy-related proteins, further supporting the roles of SLMO2 and TRIAP1 in the regulation of mitochondrial function.
Conclusions:
SLMO2 regulated mitochondrial function and inhibited apoptosis in ovarian cancer cells by interacting with TRIAP1. The combination of SLMO2 and TRIAP1 promoted tumor cell growth and induced oxidative stress, suggesting potential therapeutic targets for ovarian cancer.
Insights
SLMO2 enhances mitochondrial function and inhibits apoptosis in ovarian cancer by interacting with TRIAP1. This interaction suppresses autophagy, promoting tumor growth and oxidative stress, offering new therapeutic targets.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Ovarian cancer is a leading cause of cancer-related death in women.
- Mitochondrial dysfunction and apoptosis resistance are hallmarks of cancer.
- SLMO2 and TRIAP1 are implicated in cellular processes relevant to cancer progression.
Purpose of the Study:
- To investigate the role of SLMO2 in regulating mitochondrial function in ovarian cancer.
- To elucidate the interaction between SLMO2 and TRIAP1 and its effect on apoptosis.
- To identify potential therapeutic targets for ovarian cancer based on SLMO2 and TRIAP1 interactions.
Main Methods:
- Established lentiviral infection models in SKOV3 and OVCAR3 ovarian cancer cell lines.
- Utilized flow cytometry, western blotting, immunofluorescence, and transmission electron microscopy.
- Conducted subcutaneous mouse tumor xenograft models to assess in vivo effects.
Main Results:
- SLMO2 enhanced mitochondrial membrane potential and reduced reactive oxygen species (ROS).
- SLMO2's interaction with TRIAP1 inhibited autophagy, suppressing apoptosis and regulating mitochondrial function.
- In vivo studies confirmed elevated ROS and decreased autophagy-related proteins, supporting SLMO2/TRIAP1 roles.
Conclusions:
- SLMO2 regulates mitochondrial function and inhibits apoptosis in ovarian cancer via TRIAP1 interaction.
- Combined SLMO2 and TRIAP1 activity promotes tumor growth and oxidative stress.
- SLMO2 and TRIAP1 represent potential therapeutic targets for ovarian cancer treatment.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:30Apoptosis
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:17The Extrinsic Apoptotic Pathway